

Drug Monograph

Drug Name: **Amzeeq™ (minocycline) 4% Topical Foam**
Drug Class: **Tetracycline**
Prepared For: MO HealthNet
Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Amzeeq is a topical foam preparation available as 4% minocycline.

Manufacturer: Manufactured for: Foamix Pharmaceuticals Inc., Bridgewater, NJ 08807.

Indications: Amzeeq is indicated to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.

Costs: \$480 per 30 g. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: Tyler Woods PharmD
Date: March 4, 2020